Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

923 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.
Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, Angus SP, Collins KA, Granger DA, Reuther RA, Graves LM, Gomez SM, Kuan PF, Parker JS, Chen X, Sciaky N, Carey LA, Earp HS, Jin J, Johnson GL. Stuhlmiller TJ, et al. Among authors: duncan js. Cell Rep. 2015 Apr 21;11(3):390-404. doi: 10.1016/j.celrep.2015.03.037. Epub 2015 Apr 9. Cell Rep. 2015. PMID: 25865888 Free PMC article.
The dynamic nature of the kinome.
Graves LM, Duncan JS, Whittle MC, Johnson GL. Graves LM, et al. Among authors: duncan js. Biochem J. 2013 Feb 15;450(1):1-8. doi: 10.1042/BJ20121456. Biochem J. 2013. PMID: 23343193 Free PMC article. Review.
Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL. Zawistowski JS, et al. Among authors: duncan js. Cancer Discov. 2017 Mar;7(3):302-321. doi: 10.1158/2159-8290.CD-16-0653. Epub 2017 Jan 20. Cancer Discov. 2017. PMID: 28108460 Free PMC article. Clinical Trial.
Defining the expressed breast cancer kinome.
Midland AA, Whittle MC, Duncan JS, Abell AN, Nakamura K, Zawistowski JS, Carey LA, Earp HS 3rd, Graves LM, Gomez SM, Johnson GL. Midland AA, et al. Among authors: duncan js. Cell Res. 2012 Apr;22(4):620-3. doi: 10.1038/cr.2012.25. Epub 2012 Feb 7. Cell Res. 2012. PMID: 22310242 Free PMC article. No abstract available.
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.
Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, Hoadley KA, Zhou B, Sharpless NE, Perou CM, Kim WY, Gomez SM, Chen X, Jin J, Frye SV, Earp HS, Graves LM, Johnson GL. Duncan JS, et al. Cell. 2012 Apr 13;149(2):307-21. doi: 10.1016/j.cell.2012.02.053. Cell. 2012. PMID: 22500798 Free PMC article.
Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.
Cooper MJ, Cox NJ, Zimmerman EI, Dewar BJ, Duncan JS, Whittle MC, Nguyen TA, Jones LS, Ghose Roy S, Smalley DM, Kuan PF, Richards KL, Christopherson RI, Jin J, Frye SV, Johnson GL, Baldwin AS, Graves LM. Cooper MJ, et al. Among authors: duncan js. PLoS One. 2013 Jun 24;8(6):e66755. doi: 10.1371/journal.pone.0066755. Print 2013. PLoS One. 2013. PMID: 23826126 Free PMC article.
Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer.
Kurimchak AM, Shelton C, Duncan KE, Johnson KJ, Brown J, O'Brien S, Gabbasov R, Fink LS, Li Y, Lounsbury N, Abou-Gharbia M, Childers WE, Connolly DC, Chernoff J, Peterson JR, Duncan JS. Kurimchak AM, et al. Among authors: duncan ke, duncan js. Cell Rep. 2016 Aug 2;16(5):1273-1286. doi: 10.1016/j.celrep.2016.06.091. Epub 2016 Jul 21. Cell Rep. 2016. PMID: 27452461 Free PMC article.
Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models.
Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest AJ, Jin J, Zamboni WC, Johnson GL, Perou CM, Sharpless NE. Roberts PJ, et al. Among authors: duncan js. Clin Cancer Res. 2012 Oct 1;18(19):5290-303. doi: 10.1158/1078-0432.CCR-12-0563. Epub 2012 Aug 7. Clin Cancer Res. 2012. PMID: 22872574 Free PMC article.
923 results